Advanced Search
Search
  
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire

Other News Releases in Health Care & Hospitals

Congressman Fattah: Thanks to Specter, Casey for a Major Step Along History's Path

Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure

Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill

Other News Releases in Dividends

Central Virginia Bankshares, Inc. Declares 4th Quarter 2009 Dividend

MutualFirst Financial, Inc. Declares Cash Dividend

Unilens Vision Reports Record First Quarter Earnings and Royalty Income

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Dividends

 

PDL BioPharma Announces Record Date for October 1 Dividend Payment

INCLINE VILLAGE, Nev., June 10 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that all shareholders owning shares of PDL on September 17, 2009, will be paid a dividend of $0.50 per share on October 1, 2009. The Company previously announced that it would pay two dividends, each in the amount of $0.50 per share, to its stockholders in 2009. The first dividend was paid on April 1, 2009 to all stockholders who owned shares of PDL on March 16, 2009.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.